All Cases

Infrastructure Of Care Readiness Strategy

Characterized and segmented the treatment ecosystem for relapsing multiple sclerosis (MS) to inform patient- and ecosystem-support strategies and promote a robust launch for a small biotech

Characterized Hemophilia GTx Infusion center networks and developed processes to track and validate center readiness, informing commercial strategy and planning at a large pharmaceutical company

Developed a comprehensive understanding of the DMD GTx infrastructure of care to wholistically inform commercial planning for a large pharmaceutical company

Characterized the KOL and CoE Landscape for a pediatric dysregulation syndrome to support pre-commercialization planning at a mid-sized pharmaceutical company

Assessed UK treatment constraints and system-wide capacity for a multiple sclerosis therapy, ultimately optimizing and informing the strategic action plan of a large pharmaceutical company

Developed global view of heath systems’ capacity to administer a novel Alzheimer’s drug to inform investment decisions at a large pharmaceutical company